<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541749</url>
  </required_header>
  <id_info>
    <org_study_id>IFN3958g</org_study_id>
    <nct_id>NCT00541749</nct_id>
  </id_info>
  <brief_title>A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase I, randomized, placebo-controlled, double-blind, dose-escalation study of&#xD;
      single and repeat doses of rhuMAb IFNalpha, administered through the SC or IV route, in&#xD;
      adults with Systemic Lupus Erythematosus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and nature of laboratory abnormalities</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence, nature, and severity of adverse events</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The PK profile of rhuMAb IFNalpha</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of antibodies directed against rhuMAb IFNalpha</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhuMAb IFNalpha</intervention_name>
    <description>Intravenous repeating dose</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For patients with reproductive potential (males and females), use of a reliable means&#xD;
             of contraception (e.g., hormonal contraceptive, patch, vaginal ring, intrauterine&#xD;
             device, physical barrier) throughout their participation in the study&#xD;
&#xD;
          -  Diagnosis of SLE according to current American College of Rheumatology (ACR) criteria&#xD;
&#xD;
          -  Disease duration of â‰¥ 1 year (after first diagnosis by a physician)&#xD;
&#xD;
          -  Current immunity to measles, mumps, rubella, and varicella, as evidenced by positive&#xD;
             IgG titers at the time of screening&#xD;
&#xD;
          -  Current vaccination against influenza unless contraindicated in the investigator's&#xD;
             judgment&#xD;
&#xD;
          -  Normal Pap smear within the applicable time interval recommended by current American&#xD;
             Cancer Society guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of active lupus nephritis&#xD;
&#xD;
          -  Presence of active central nervous system (CNS) disease requiring treatment with&#xD;
             high-dose corticosteroids or immunosuppressive agents&#xD;
&#xD;
          -  Presence of active vasculitis requiring treatment&#xD;
&#xD;
          -  History of arterial or venous thromboses within 12 months of screening&#xD;
&#xD;
          -  Moderate to severe anemia, thrombocytopenia, or neutropenia&#xD;
&#xD;
          -  Any manifestation likely to require, in the investigator's judgment, treatment with&#xD;
             high-dose corticosteroids or the addition of an immunosuppressive regimen during the&#xD;
             course of the trial&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Lack of peripheral venous access&#xD;
&#xD;
          -  History of alcohol or substance abuse within 6 months of screening&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to antibodies or fusion proteins&#xD;
&#xD;
          -  Evidence of significant uncontrolled concomitant diseases&#xD;
&#xD;
          -  Significant laboratory or electrocardiogram (ECG) abnormalities&#xD;
&#xD;
          -  Evidence of any clinically significant abnormality on a chest X-ray&#xD;
&#xD;
          -  Severly impaired renal function&#xD;
&#xD;
          -  Impaired hepatic function&#xD;
&#xD;
          -  Poorly controlled diabetes&#xD;
&#xD;
          -  Conditions other than SLE that could require treatment with corticosteroids&#xD;
&#xD;
          -  History of malignancy except completely excised basal cell carcinoma&#xD;
&#xD;
          -  Congenital immune deficiency&#xD;
&#xD;
          -  Positive tests for antibodies to HIV, hepatitis B (HBS antigen, anti-HBC) or C&#xD;
&#xD;
          -  Positive IgM antibody titers in the presence of negative IgG titers to Epstein-Barr&#xD;
             virus (EBV) or cytomegalovirus (CMV)&#xD;
&#xD;
          -  Frequent recurrence of herpes lesions&#xD;
&#xD;
          -  Episode of shingles within one year of screening&#xD;
&#xD;
          -  Positive screening test for latent mycobacterium tuberculosis infection&#xD;
&#xD;
          -  History of severe systemic bacterial, fungal, viral, or parasitic infections within&#xD;
             the year prior to screening&#xD;
&#xD;
          -  Any current or recent signs or symptoms of infection&#xD;
&#xD;
          -  Received antibiotics orally (PO) during the 30 days prior to screening or IV&#xD;
             antibiotics during the 60 days prior to screening&#xD;
&#xD;
          -  Received a live vaccine within the 30 days prior to screening&#xD;
&#xD;
          -  Has been hospitalized within the 30 days prior to screening&#xD;
&#xD;
          -  Received &gt; 20 mg/day prednisone for &gt; 3 days during the 30 days prior to screening&#xD;
&#xD;
          -  Received azathioprine, methotrexate, mycophenolate mofetil, cyclosporine, tacrolimus,&#xD;
             sirolimus, pulse dose corticosteroids, intravenous immunoglobulin (IVIG), or&#xD;
             transfusions within 6 months prior to screening&#xD;
&#xD;
          -  Received cyclophosphamide within 2 years prior to screening&#xD;
&#xD;
          -  Received a monoclonal antibody during the 12 months prior to screening&#xD;
&#xD;
          -  Previously received an investigational treatment directed against interferon alpha&#xD;
&#xD;
          -  Received B-cell depleting therapy (e.g., anti-CD20, anti-CD22)&#xD;
&#xD;
          -  Received investigational treatment during the 30 days prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorn Drappa, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>October 7, 2007</study_first_submitted>
  <study_first_submitted_qc>October 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2007</study_first_posted>
  <last_update_submitted>September 21, 2011</last_update_submitted>
  <last_update_submitted_qc>September 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SLE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

